<DOC>
	<DOC>NCT00765414</DOC>
	<brief_summary>This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in a single patient with infantile-onset Pompe disease who were previously treated with rhGAA in a Genzyme study.</brief_summary>
	<brief_title>Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Provide written informed consent prior to participating in any study related procedures; Currently enrolled in Protocol AGLU01402 Have the ability to comply with the clinical protocol, which required extensive clinical evaluations for an extended period of time. Was pregnant or unwilling to use approved birth control during the course of the study; Had experienced any unmanageable AEs under Protocol AGLU01402 (as determined and agreed upon by the Principal Investigator and sponsor) due to rhGAA that would preclude continuing ERT; Was participating in any other investigational study.</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>